The genetic toxicology testing market size has grown rapidly in recent years. It will grow from $1.48 billion in 2023 to $1.63 billion in 2024 at a compound annual growth rate (CAGR) of 10%. The growth observed in the historical period can be attributed to several key factors, including escalating public health crises, the impact of increasing globalization, heightened emphasis on personalized medicine, growing demand for robust testing solutions, and a rising number of pharmaceutical drugs entering the market.
The genetic toxicology testing market size is expected to see rapid growth in the next few years. It will grow to $2.4 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. Anticipated growth in the forecast period can be attributed to several factors, including an increased demand for testing novel foods, growing concerns regarding potential risks associated with various substances, heightened environmental and health awareness, escalating regulatory scrutiny, the expanded utilization of in vitro testing methods, and the emergence of high-throughput screening platforms. Key trends expected in the forecast period encompass advancements in precision medicine and toxicogenomics, comprehensive risk communication strategies, developments in genetic toxicology testing methodologies, progress in risk assessment methodologies, the integration of omics technologies into testing protocols, and advancements in genomics and molecular biology techniques.
The surge in demand for personalized medicine is anticipated to drive the expansion of the genetic toxicology testing market in the coming years. Personalized medicine, a healthcare approach that tailors interventions and products to individual patients based on their predicted response or disease risk, has gained traction due to genetic advancements, improved disease understanding, biomarker-based diagnostics availability, value-based healthcare initiatives, and integration into clinical practice and research. Genetic toxicology testing plays a vital role in personalized medicine by furnishing crucial insights into genetic variability, susceptibility to genotoxic agents, and treatment response. For instance, as reported by the Personalized Medicine Coalition in February 2024, the FDA greenlit 16 new personalized medicines for rare disease patients in 2023, a significant increase from six in 2022. Thus, the growing demand for personalized medicine serves as a catalyst for the genetic toxicology testing market.
Major players in the genetic toxicology testing market are concentrating on developing innovative drug screening platforms such as phenotypic drug screening to enhance accuracy and efficiency in identifying potential genetic toxins. Phenotypic drug screening involves testing compounds based on their capacity to elicit a specific cellular or physiological response in a whole organism or relevant cell system. For example, in August 2022, Creative Biogene, a US-based biotechnology company, unveiled zebrafish disease models tailored to support drug discovery and toxicology research. These models replicate human genetic diseases in zebrafish, offering insights into disease mechanisms, drug discovery, and toxicology. Creative Biogene's zebrafish models serve as a valuable tool for evaluating drug toxicity, predicting the safety of novel compounds, and bolstering the drug development pipeline.
In June 2021, Charles River Laboratories International Inc., a US-based chemical manufacturer, completed the acquisition of Vigene Biosciences for approximately $292.5 million in cash. This strategic move aims to bolster Charles River Laboratories' gene therapy capabilities in the burgeoning cell and gene therapy contract development and manufacturing organization (CDMO) sectors. Vigene Biosciences Inc., headquartered in the US, specializes in viral vector-based gene delivery technologies for life science research, gene therapy, and cell therapy applications, offering genetic toxicology testing services as part of its CDMO offerings.
Major companies operating in the genetic toxicology testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, SGS SA, WuXi AppTec, Intertek Group plc, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Fraunhofer ITEM, Jubilant Life Sciences Limited, Evotec SE, Inotiv Inc., Promega Corporation, Syngene International Limited, Nelson Laboratories LLC, Instem, Frontage Laboratories Inc., Creative Bioarray, Creative Biolabs Inc., Gentronix Limited, MB Research Laboratories.
North America was the largest region in the genetic toxicology testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genetic toxicology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genetic toxicology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Genetic toxicology testing is a specialized field within toxicology dedicated to assessing the potential of chemical substances to cause damage to genetic material, including DNA, RNA, and chromosomes. Its primary objective is to determine the genotoxicity of compounds and identify any adverse effects they may have on the genetic material of living organisms, including humans. This testing serves as a crucial tool for evaluating the safety of pharmaceuticals, chemicals, and environmental pollutants, particularly concerning genotoxic hazards.
The primary classifications within the genetic toxicology testing market include in vitro and in vivo methodologies. In vitro testing refers to experiments or studies conducted in a controlled laboratory environment, such as test tubes, petri dishes, or other artificial settings, without the involvement of living organisms. Various products encompass services, reagents, consumables, and assays, utilized across diverse applications spanning the healthcare, food, cosmetics, agriculture industries, among others.
The genetic toxicology testing market research report is one of a series of new reports that provides genetic toxicology testing market statistics, including the genetic toxicology testing industry's global market size, regional shares, competitors with a genetic toxicology testing market share, detailed genetic toxicology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the genetic toxicology testing industry. This genetic toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The genetic toxicology testing market includes revenues earned by entities through mutagenicity testing, genotoxicity screening, carcinogenicity testing, regulatory compliance, risk assessment, bacterial mutation assays, comet assays, micronucleus tests, presymptomatic testing, ancestry testing, and nutrigenomics testing, and related cell culture systems, assay kits, microscopes, flow cytometers, automation and robotics, and flow cytometry. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The genetic toxicology testing market size is expected to see rapid growth in the next few years. It will grow to $2.4 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. Anticipated growth in the forecast period can be attributed to several factors, including an increased demand for testing novel foods, growing concerns regarding potential risks associated with various substances, heightened environmental and health awareness, escalating regulatory scrutiny, the expanded utilization of in vitro testing methods, and the emergence of high-throughput screening platforms. Key trends expected in the forecast period encompass advancements in precision medicine and toxicogenomics, comprehensive risk communication strategies, developments in genetic toxicology testing methodologies, progress in risk assessment methodologies, the integration of omics technologies into testing protocols, and advancements in genomics and molecular biology techniques.
The surge in demand for personalized medicine is anticipated to drive the expansion of the genetic toxicology testing market in the coming years. Personalized medicine, a healthcare approach that tailors interventions and products to individual patients based on their predicted response or disease risk, has gained traction due to genetic advancements, improved disease understanding, biomarker-based diagnostics availability, value-based healthcare initiatives, and integration into clinical practice and research. Genetic toxicology testing plays a vital role in personalized medicine by furnishing crucial insights into genetic variability, susceptibility to genotoxic agents, and treatment response. For instance, as reported by the Personalized Medicine Coalition in February 2024, the FDA greenlit 16 new personalized medicines for rare disease patients in 2023, a significant increase from six in 2022. Thus, the growing demand for personalized medicine serves as a catalyst for the genetic toxicology testing market.
Major players in the genetic toxicology testing market are concentrating on developing innovative drug screening platforms such as phenotypic drug screening to enhance accuracy and efficiency in identifying potential genetic toxins. Phenotypic drug screening involves testing compounds based on their capacity to elicit a specific cellular or physiological response in a whole organism or relevant cell system. For example, in August 2022, Creative Biogene, a US-based biotechnology company, unveiled zebrafish disease models tailored to support drug discovery and toxicology research. These models replicate human genetic diseases in zebrafish, offering insights into disease mechanisms, drug discovery, and toxicology. Creative Biogene's zebrafish models serve as a valuable tool for evaluating drug toxicity, predicting the safety of novel compounds, and bolstering the drug development pipeline.
In June 2021, Charles River Laboratories International Inc., a US-based chemical manufacturer, completed the acquisition of Vigene Biosciences for approximately $292.5 million in cash. This strategic move aims to bolster Charles River Laboratories' gene therapy capabilities in the burgeoning cell and gene therapy contract development and manufacturing organization (CDMO) sectors. Vigene Biosciences Inc., headquartered in the US, specializes in viral vector-based gene delivery technologies for life science research, gene therapy, and cell therapy applications, offering genetic toxicology testing services as part of its CDMO offerings.
Major companies operating in the genetic toxicology testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, SGS SA, WuXi AppTec, Intertek Group plc, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Fraunhofer ITEM, Jubilant Life Sciences Limited, Evotec SE, Inotiv Inc., Promega Corporation, Syngene International Limited, Nelson Laboratories LLC, Instem, Frontage Laboratories Inc., Creative Bioarray, Creative Biolabs Inc., Gentronix Limited, MB Research Laboratories.
North America was the largest region in the genetic toxicology testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genetic toxicology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genetic toxicology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Genetic toxicology testing is a specialized field within toxicology dedicated to assessing the potential of chemical substances to cause damage to genetic material, including DNA, RNA, and chromosomes. Its primary objective is to determine the genotoxicity of compounds and identify any adverse effects they may have on the genetic material of living organisms, including humans. This testing serves as a crucial tool for evaluating the safety of pharmaceuticals, chemicals, and environmental pollutants, particularly concerning genotoxic hazards.
The primary classifications within the genetic toxicology testing market include in vitro and in vivo methodologies. In vitro testing refers to experiments or studies conducted in a controlled laboratory environment, such as test tubes, petri dishes, or other artificial settings, without the involvement of living organisms. Various products encompass services, reagents, consumables, and assays, utilized across diverse applications spanning the healthcare, food, cosmetics, agriculture industries, among others.
The genetic toxicology testing market research report is one of a series of new reports that provides genetic toxicology testing market statistics, including the genetic toxicology testing industry's global market size, regional shares, competitors with a genetic toxicology testing market share, detailed genetic toxicology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the genetic toxicology testing industry. This genetic toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The genetic toxicology testing market includes revenues earned by entities through mutagenicity testing, genotoxicity screening, carcinogenicity testing, regulatory compliance, risk assessment, bacterial mutation assays, comet assays, micronucleus tests, presymptomatic testing, ancestry testing, and nutrigenomics testing, and related cell culture systems, assay kits, microscopes, flow cytometers, automation and robotics, and flow cytometry. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Genetic Toxicology Testing Market Characteristics3. Genetic Toxicology Testing Market Trends and Strategies32. Global Genetic Toxicology Testing Market Competitive Benchmarking33. Global Genetic Toxicology Testing Market Competitive Dashboard34. Key Mergers and Acquisitions in the Genetic Toxicology Testing Market
4. Genetic Toxicology Testing Market - Macro Economic Scenario
5. Global Genetic Toxicology Testing Market Size and Growth
6. Genetic Toxicology Testing Market Segmentation
7. Genetic Toxicology Testing Market Regional and Country Analysis
8. Asia-Pacific Genetic Toxicology Testing Market
9. China Genetic Toxicology Testing Market
10. India Genetic Toxicology Testing Market
11. Japan Genetic Toxicology Testing Market
12. Australia Genetic Toxicology Testing Market
13. Indonesia Genetic Toxicology Testing Market
14. South Korea Genetic Toxicology Testing Market
15. Western Europe Genetic Toxicology Testing Market
16. UK Genetic Toxicology Testing Market
17. Germany Genetic Toxicology Testing Market
18. France Genetic Toxicology Testing Market
19. Italy Genetic Toxicology Testing Market
20. Spain Genetic Toxicology Testing Market
21. Eastern Europe Genetic Toxicology Testing Market
22. Russia Genetic Toxicology Testing Market
23. North America Genetic Toxicology Testing Market
24. USA Genetic Toxicology Testing Market
25. Canada Genetic Toxicology Testing Market
26. South America Genetic Toxicology Testing Market
27. Brazil Genetic Toxicology Testing Market
28. Middle East Genetic Toxicology Testing Market
29. Africa Genetic Toxicology Testing Market
30. Genetic Toxicology Testing Market Competitive Landscape and Company Profiles
31. Genetic Toxicology Testing Market Other Major and Innovative Companies
35. Genetic Toxicology Testing Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Genetic Toxicology Testing Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on genetic toxicology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for genetic toxicology testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genetic toxicology testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: In Vitro; In Vivo2) By Product: Services; Reagents And Consumables; Assays
3) By Application: Healthcare Industry; Food Industry; Cosmetics Industry; Agriculture Industry; Other Applications
Key Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Merck KGaA; Laboratory Corporation of America Holdings
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Merck KGaA
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Eurofins Scientific SE
- SGS SA
- WuXi AppTec
- Intertek Group plc
- Charles River Laboratories International Inc.
- PerkinElmer Inc.
- Bio-Rad Laboratories Inc.
- Fraunhofer ITEM
- Jubilant Life Sciences Limited
- Evotec SE
- Inotiv Inc.
- Promega Corporation
- Syngene International Limited
- Nelson Laboratories LLC
- Instem
- Frontage Laboratories Inc.
- Creative Bioarray
- Creative Biolabs Inc.
- Gentronix Limited
- MB Research Laboratories
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 1.63 Billion |
Forecasted Market Value ( USD | $ 2.4 Billion |
Compound Annual Growth Rate | 10.2% |
Regions Covered | Global |